FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993758901> ?p ?o ?g. }

• W1993758901 endingPage "845" @default.
• W1993758901 startingPage "839" @default.
• W1993758901 abstract "Daclizumab (Zenapax, Roche Pharmaceuticals), a humanized monoclonal antibody directed against the alpha chain of the interleukin 2 receptor, has been shown to reduce the incidence of acute rejection at 6 months after renal transplantation in two phase III clinical trials. This report presents the combined 1- and 3-year outcomes of kidney transplant recipients who participated in these two phase III clinical trials.Data from two multicenter, randomized, placebo-controlled trials were evaluated with regard to graft survival, patient survival, incidence of malignancies (including lymphoma), renal function (serum creatinine and glomerular filtration rate [GFR]), and current maintenance immunosuppressive regimen. In addition, the impact of acute rejection and acute rejection requiring treatment with antilymphocyte therapy upon 3-year graft survival was evaluated. Daclizumab was compared to placebo on a background of cyclosporine (CsA), azathioprine, and corticosteroids (triple therapy, TT) or CsA and corticosteroids (double therapy, DT).Treatment with daclizumab in the pooled analysis demonstrated a significant reduction in the incidence of biopsy-proven acute rejection episodes at 12 months posttransplant (43% vs. 28%, P<0.001). The 3-year graft survival was not significantly different between placebo and daclizumab-treated patients in the TT trial (83% vs. 84%) or in the DT trial (78% vs. 82%). Pooled patient survival was excellent in both placebo- (91%) and daclizumab- (93%) treated patients. The incidence of malignancies or posttransplant lymphoproliferative disorder (PTLD) in placebo- versus daclizumab-treated groups was comparable in both clinical trials. Renal function was similar between placebo- and daclizumab-treated groups in both the TT and DT trials. The occurrence of delayed graft function, acute rejection requiring antilymphocyte therapy at 6 months, and acute rejection at 12 months posttransplant were associated with decreased graft survival rates at 3 years posttransplant.The beneficial effect of daclizumab prophylaxis upon the incidence of acute rejection after renal transplant with TT or with DT was not associated with adverse clinical sequelae, including the development of PTLD, at 3 years posttransplant. There was no beneficial effect of daclizumab on graft survival at 3 years, but the trial was inadequately powered to detect this. Both studies showed excellent graft and patient survival at 3 years." @default.
• W1993758901 created "2016-06-24" @default.
• W1993758901 creator A5007122777 @default.
• W1993758901 creator A5026789430 @default.
• W1993758901 creator A5042236941 @default.
• W1993758901 creator A5044825904 @default.
• W1993758901 creator A5055314788 @default.
• W1993758901 creator A5058779959 @default.
• W1993758901 creator A5066597115 @default.
• W1993758901 creator A5076249045 @default.
• W1993758901 date "2001-09-01" @default.
• W1993758901 modified "2023-10-10" @default.
• W1993758901 title "RESULTS OF 3-YEAR PHASE III CLINICAL TRIALS WITH DACLIZUMAB PROPHYLAXIS FOR PREVENTION OF ACUTE REJECTION AFTER RENAL TRANSPLANTATION1" @default.
• W1993758901 cites W1756759934 @default.
• W1993758901 cites W2050421097 @default.
• W1993758901 cites W2052150715 @default.
• W1993758901 cites W2060508116 @default.
• W1993758901 cites W2093603781 @default.
• W1993758901 cites W2125199942 @default.
• W1993758901 cites W2158687372 @default.
• W1993758901 cites W4253993810 @default.
• W1993758901 cites W68282923 @default.
• W1993758901 doi "https://doi.org/10.1097/00007890-200109150-00017" @default.
• W1993758901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11571447" @default.
• W1993758901 hasPublicationYear "2001" @default.
• W1993758901 type Work @default.
• W1993758901 sameAs 1993758901 @default.
• W1993758901 citedByCount "96" @default.
• W1993758901 countsByYear W19937589012012 @default.
• W1993758901 countsByYear W19937589012013 @default.
• W1993758901 countsByYear W19937589012014 @default.
• W1993758901 countsByYear W19937589012016 @default.
• W1993758901 countsByYear W19937589012017 @default.
• W1993758901 countsByYear W19937589012018 @default.
• W1993758901 countsByYear W19937589012019 @default.
• W1993758901 countsByYear W19937589012020 @default.
• W1993758901 countsByYear W19937589012022 @default.
• W1993758901 countsByYear W19937589012023 @default.
• W1993758901 crossrefType "journal-article" @default.
• W1993758901 hasAuthorship W1993758901A5007122777 @default.
• W1993758901 hasAuthorship W1993758901A5026789430 @default.
• W1993758901 hasAuthorship W1993758901A5042236941 @default.
• W1993758901 hasAuthorship W1993758901A5044825904 @default.
• W1993758901 hasAuthorship W1993758901A5055314788 @default.
• W1993758901 hasAuthorship W1993758901A5058779959 @default.
• W1993758901 hasAuthorship W1993758901A5066597115 @default.
• W1993758901 hasAuthorship W1993758901A5076249045 @default.
• W1993758901 hasBestOaLocation W19937589011 @default.
• W1993758901 hasConcept C126322002 @default.
• W1993758901 hasConcept C126894567 @default.
• W1993758901 hasConcept C141071460 @default.
• W1993758901 hasConcept C142724271 @default.
• W1993758901 hasConcept C159641895 @default.
• W1993758901 hasConcept C204787440 @default.
• W1993758901 hasConcept C27081682 @default.
• W1993758901 hasConcept C2779719350 @default.
• W1993758901 hasConcept C2780303639 @default.
• W1993758901 hasConcept C2909675724 @default.
• W1993758901 hasConcept C2911091166 @default.
• W1993758901 hasConcept C535046627 @default.
• W1993758901 hasConcept C71924100 @default.
• W1993758901 hasConcept C90924648 @default.
• W1993758901 hasConceptScore W1993758901C126322002 @default.
• W1993758901 hasConceptScore W1993758901C126894567 @default.
• W1993758901 hasConceptScore W1993758901C141071460 @default.
• W1993758901 hasConceptScore W1993758901C142724271 @default.
• W1993758901 hasConceptScore W1993758901C159641895 @default.
• W1993758901 hasConceptScore W1993758901C204787440 @default.
• W1993758901 hasConceptScore W1993758901C27081682 @default.
• W1993758901 hasConceptScore W1993758901C2779719350 @default.
• W1993758901 hasConceptScore W1993758901C2780303639 @default.
• W1993758901 hasConceptScore W1993758901C2909675724 @default.
• W1993758901 hasConceptScore W1993758901C2911091166 @default.
• W1993758901 hasConceptScore W1993758901C535046627 @default.
• W1993758901 hasConceptScore W1993758901C71924100 @default.
• W1993758901 hasConceptScore W1993758901C90924648 @default.
• W1993758901 hasIssue "5" @default.
• W1993758901 hasLocation W19937589011 @default.
• W1993758901 hasLocation W19937589012 @default.
• W1993758901 hasLocation W19937589013 @default.
• W1993758901 hasOpenAccess W1993758901 @default.
• W1993758901 hasPrimaryLocation W19937589011 @default.
• W1993758901 hasRelatedWork W1966250111 @default.
• W1993758901 hasRelatedWork W1999001339 @default.
• W1993758901 hasRelatedWork W2008490960 @default.
• W1993758901 hasRelatedWork W2050173858 @default.
• W1993758901 hasRelatedWork W2074936215 @default.
• W1993758901 hasRelatedWork W2090639386 @default.
• W1993758901 hasRelatedWork W2093387344 @default.
• W1993758901 hasRelatedWork W2362687898 @default.
• W1993758901 hasRelatedWork W2379160126 @default.
• W1993758901 hasRelatedWork W2993868296 @default.
• W1993758901 hasVolume "72" @default.
• W1993758901 isParatext "false" @default.
• W1993758901 isRetracted "false" @default.
• W1993758901 magId "1993758901" @default.
• W1993758901 workType "article" @default.